Genomic DNA at additional programmed loci

Genomic DNA at additional programmed loci refers to specific sequences within the human genome that are intentionally targeted for modification using precision genome-editing tools such as CRISPR-Cas9, TALENs, or Zinc Finger Nucleases (NIH, 2023). These loci are designated as "programmed" because the therapeutic machinery is engineered with specific guide RNAs or DNA-binding domains to recognize and bind these exact coordinates (Nature, 2022). In clinical applications, particularly in the development of "off-the-shelf" allogeneic CAR-T cells, these additional loci often involve genes that regulate immune evasion or histocompatibility, such as the TRAC or B2M loci (PubMed, 2021). By modifying these sites, researchers can enhance the therapeutic profile of cell-based medicines, such as increasing persistence in the tumor microenvironment or preventing graft-versus-host disease (Frontiers in Immunology, 2020). The interaction with drugs involves the physical binding of the editing complex to the DNA, followed by enzymatic cleavage or chemical modification of the nucleotide bases (PubChem, 2024). However, targeting these loci requires rigorous validation to avoid off-target effects and ensure genomic stability, as unintended breaks in the DNA can lead to oncogenic transformations or chromosomal translocations (FDA, 2024). Monitoring these loci via next-generation sequencing is essential for assessing the safety and efficacy of the gene-editing process (Cell, 2023).

Other names

Programmed genomic lociTargeted DNA sequencesGene editing target sitesEngineered genomic loci

Site-specific DNA modification via CRISPR-Cas9 or other nucleases to achieve gene knockout, knockdown, or insertion.